Sen. Justin Brown

Maddy summarySB 1533 would create a compact allowing dentists and dental hygienists to practice across participating states without obtaining separate licenses in each. It establishes mutual recognition of licenses between states that join the compact, eliminating the need for duplicate exams or paperwork when moving between member states. This directly affects dental professionals seeking to work in multiple states, streamlining their ability to practice. The bill is currently in committee review after its first reading in January 2026.

SB 1454 - This act modifies current law on the use of investigational drugs and devices for individuals with terminal illnesses to include those individuals with life-threatening or severely debilitating conditions or illnesses. Currently, investigational drugs shall not include Schedule I controlled substances. This act repeals that prohibition. This act is substantially similar to provisions in SB 1682 (2026, SCS/SB 90 (2025), SB 1767 (2026), SCS/HCS/HBs 1717 & 1643 (2026), SCS/HS/HCS/HBs 3068 & 3049 (2026), and SCS/SB 768 (2024). SARAH HASKINS

Maddy summaryThis bill's description lacks specific details about its provisions or changes. The official title and abstract only state it "modifies provisions relating to telemedicine" without outlining concrete changes, affected parties, or key mechanisms. No further information about the bill's content, sponsors, or intended impacts is provided in the available context. As it is a procedural modification with no substantive details shared, a meaningful summary cannot be generated.

SB 846 - This act enacts provisions relating to insurance coverage of pharmacy services. CLINICIAN-ADMINISTERED DRUGS (Section 376.411) This act provides that a health carrier or pharmacy benefits manager (PBM) shall not impose any penalty, impediment, differentiation, or limitation on participating providers for providing medically necessary clinician-administered drugs, regardless of whether the participating provider obtains the drugs from an in-network provider, including but not limited to refusing to approve or pay, or reimbursing less than the contracted payment amount. Carriers and PBMs shall not impose any penalty, impediment, differentiation, or limitation on a covered person who is administered medically necessary clinician-administered drugs, regardless of whether the participating provider obtains the drugs from an in-network provider, including but not limited to: limiting coverage or benefits; requiring an additional fee, higher co-payment, or higher coinsurance amount; or interfering with a patient's ability to obtain a clinician-administered drug from the patient's provider or pharmacy of choice by any means, including but not limited to inducing, steering, or offering financial or other incentives. Carriers and PBMs shall not impose any penalty, impediment, differentiation, or limitation on any pharmacy that is dispensing medically necessary clinician-administered drugs, regardless of whether the participating provider obtains the drugs from an in-network provider, including but not limited to requiring a pharmacy to dispense the drugs to a patient with the intention that the patient will transport the medication to a health care provider for administration. These provisions shall not apply if the clinician-administered drug is not otherwise covered by the carrier or PBM. These provisions are identical to provisions in SB 13 (2025), the introduced SB 751 (2024), HCS/HB 2267 (2024), SB 26 (2023), HCS/HB 198 (2023), SB 1129 (2022), and HB 2305 (2022), and similar to provisions in SB 921 (2022), SB 1129 (2022), and HB 2305 (2022). REFERENCE PRODUCTS AND BIOSIMILARS (Section 376.415) A health carrier or PBM providing coverage for a reference product or a biological product that is biosimilar to the reference product shall provide coverage for the reference product and all biological products that have been deemed biosimilar to the reference product. The scope, extent, and amount of the required coverage shall be the same, including but not limited to any payment limitations or cost-sharing obligations. These provisions are identical to provisions in SB 13 (2025), the introduced SB 751 (2024), HCS/HB 2267 (2024), SB 26 (2023), HCS/HB 198 (2023), SB 1129 (2022), and HB 2305 (2022), and similar to provisions in SB 921 (2022), SB 1129 (2022), and HB 2305 (2022). 340B DRUG PRICING PROGRAM (Section 376.416) Under this act, no health carrier or pharmacy benefits manager (PBM) shall discriminate against a covered entity or a pharmacy, as such terms are defined in the act, by: • Reimbursing a covered entity or pharmacy for a quantity of a 340B drug, as defined in the act, in an amount less than the carrier, PBM, or affiliate would pay to any other similarly situated pharmacy for such quantity of the drug on the basis that the entity or pharmacy is a covered entity or a pharmacy, or that the entity or pharmacy dispenses 340B drugs. (Section 376.416.2(1)); • Imposing any terms or conditions on covered entities or pharmacies which differ from the terms or conditions applicable to other similarly situated pharmacies or entities on the basis that the entity or pharmacy is a covered entity or dispenses 340B drugs, including but not limited to certain terms and conditions described in the act. (Section 376.416.2(2)); • Interfering with an individual's choice to receive a 340B drug from a covered entity or pharmacy. (Section 376.416.2(3)); • Discriminating in reimbursement to a covered entity or pharmacy based on the determination or indication a drug is a 340B drug. (Section 376.416.2(4)); • Requiring a covered entity or pharmacy to identify a 340B drug sooner than 45 days after the point of sale of the drug. (Section 376.416.2(5)); • Refusing to contract with a covered entity or pharmacy for reasons other than those that apply equally to entities or pharmacies that are not covered entities or similarly situated pharmacies, or on the basis that the entity or pharmacy is a covered entity as described under federal law, or on the basis that the entity or pharmacy is described as a covered entity under provisions of federal law. (Section 376.416.2(6)); • Denying the covered entity the ability to purchase drugs at 340B program pricing by substituting a rebate discount. (Section 376.416.2(7)); • Refusing to cover drugs purchased under the 340B drug pricing program. (Section 376.416.2(8)); or • Requiring a covered entity or pharmacy to reverse, resubmit, or clarify a 340B-drug pricing claim after the initial adjudication unless these actions are in the normal course of pharmacy business and not related to the 340B drug pricing, except as required by federal law. (Section 376.416.2(9)). The Director of the Department of Commerce and Insurance shall impose a civil penalty on any health carrier or PBM violating certain provisions of the act, not to exceed $5,000 per violation per day. (Section 376.416.3). These provisions are identical to provisions in SB 13 (2025), and similar to provisions in SB 372 (2025), HB 784 (2025), HB 785 (2025), HB 943 (2025), the introduced SB 751 (2024), SCS/SBs 978 & 1035 (2024), SB 1213 (2024), HCS/HB 2267 (2024), HB 1977 (2024), SB 26 (2023), HCS/HB 198 (2023), SB 426 (2023), HB 197 (2023), SB 921 (2022), HCS/HB 1677 (2022), SB 1129 (2022), and HB 2305 (2022). PRIOR AUTHORIZATION OF HEALTH CARE SERVICES (Sections 376.2100, 376.2102, 376.2104, 376.2106, and 376.2108) This act enacts provisions relating to prior authorization of health care services. Beginning January 1, 2027, health care providers shall not be required to obtain prior authorization for a health care service unless the health carrier or utilization review entity determines that in the most recent evaluation period, as defined in the act, less than 90% of the prior authorization requests submitted by that provider for that health care service were approved or would have been approved. Also beginning January 1, 2027, health care providers shall not be required to obtain prior authorization for any health care services unless the health carrier or utilization review entity has approved or would have approved less than 90% of all prior authorization requests submitted by that provider for health care services. Health carriers or utilization review entities may elect to have certain hospitals determine which of certain conditions, laid out in the act, the hospital will comply with in order to obtain a prior authorization exemption under the act. Exemptions from prior authorization under the act shall not apply to: pharmacy services, not to exceed the amount of $100,000; imaging services, not to exceed $100,000; cosmetic procedures that are not medically necessary; or investigative or experimental treatments. Maximum dollar amounts for these exceptions shall be adjusted annually for inflation as described in the act. The act further specifies certain prior authorization requests that shall not be included in making determinations under the act, specifies identification methods for the providers, includes provisions for the auditing and retraction of determinations under the act, allows for health carriers and utilization review entities to require providers to use an online portal to submit prior authorization requests, requires adverse determinations under the act to be reviewed by a clinical peer of the provider, and requires a grace period for patients who have received prior authorization for a 90-day supply of medication. Health carriers and utilization review entities shall notify providers within 25 days after a determination is made under the act, shall include in the notification certain information used in making the determination, shall establish an appeals process for the providers, and shall maintain an online prior authorization portal as described in the act. No health carrier or utilization review entity shall deny or reduce payment to a health care provider for a health care service for which the provider has prior authorization, except as described in the act. These provisions shall not apply to MO HealthNet services not provided through a managed care organization, or to providers who have not participated in a health benefit plan offered by the health carrier for at least one full evaluation period. These provisions are identical to provisions contained in SB 841 (2026), SB 13 (2025), HCS/SS#2/SB 79 (2025), HB 618 (2025), and similar to SB 897 (2026), HCS/HB 3010 (2026), HB 1675 (2026), SB 230 (2025), SB 751 (2024), SB 983 (2024), HB 1976 (2024), HB 2267 (2024), SB 576 (2023), and HB 1045 (2023). TAYLOR MIDDLETON

Maddy summarySB 940 modifies Missouri's peer review committee rules to require hospitals to provide all necessary medical records and quality documentation to the state department, or risk losing their trauma, STEMI, or stroke center designations. It expands the definition of "health care professional" to include those licensed under specific healthcare laws and clarifies that quality improvement activities under these laws count as peer review committee work. The bill strengthens confidentiality protections, making peer review discussions, records, and recommendations privileged and non-discoverable in court, while maintaining immunity for committee members acting in good faith. These changes directly affect hospitals seeking to maintain specialty center designations, healthcare providers participating in peer reviews, and the state department overseeing these processes.

Maddy summaryDespite its title, SB 14 primarily modifies Missouri's state income tax structure and establishes a new funding mechanism for disaster relief. The bill reduces the top individual income tax rate for residents, with an initial reduction taking effect in 2023 and potential for further reductions contingent on state revenue growth. Additionally, beginning in 2026 and expiring at the end of 2028, it imposes an extra 1% tax on taxable income exceeding $1 million. Revenues from this additional tax will be credited to a newly created Disaster Relief Fund, managed by the Department of Public Safety, to provide aid for governor-declared disasters and emergencies. Seventy-five percent of these funds are reserved for emergencies in cities not within a county, with the remainder for other areas.

Maddy summarySB 190 establishes tax credits for individuals. These credits are specifically available to those who have obtained certain engineering degrees. The bill's core provision is to allow a reduction in tax liability for eligible degree holders.

Maddy summaryThis bill (SB 189) modifies existing public safety provisions, but the provided context does not specify the exact changes or which groups or agencies are directly affected. The official abstract only states it "modifies provisions relating to public safety" without detailing the specific mechanisms or policy shifts. Recent actions show the bill is currently in conference committee (as of May 14, 2025), with House and Senate conferees appointed to resolve differences between the versions passed by each chamber. No concrete policy details or affected parties are described in the available information.

Maddy summaryBased on the provided information, SB 107 modifies existing provisions that relate to peer review committees. The abstract does not specify the nature of these modifications or the specific impact on the committees or other entities. More details would be needed to explain the bill's specific mechanisms or who it directly affects.

Maddy summaryThe provided context does not include specific details about SB 537's provisions, affected parties, or mechanisms. The official abstract only states the bill's title ("Missouri Defense and Energy Independence Act") without explaining its content. Without additional information on what the bill actually does or its key policy changes, a substantive summary cannot be created. Please provide the bill's full text or a detailed summary for an accurate response.